+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 50Years - 85Years
FEMALE
ID07406685

Comparing Ibandronate and Zoledronic Acid as Sequential Therapy After Stopping Denosumab in Postmenopausal Women with Osteoporosis

Led by National Taiwan University Hospital · Updated on 2026-08-25

52

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating intravenous ibandronate and zoledronic acid as sequential treatments after stopping denosumab in postmenopausal women with osteoporosis who have used denosumab for less than three years. This open-label, randomized trial aims to provide early evidence on whether ibandronate offers similar protection as zoledronic acid, which is the current standard, to help inform future studies of longer-term denosumab use. Participants will be randomly assigned to receive either ibandronate at 3 mg every 3 months for 12 months or a single dose of zoledronic acid 5 mg over one year, starting about six months after their last denosumab injection. Following treatment, they will be monitored for a total of two years to observe the effects of these therapies on bone health. During the study, participants will undergo bone mineral density scans and have blood tests to measure bone turnover markers at baseline and throughout the 24-month period. Researchers will also assess pain levels using a visual analog scale and track any osteoporotic fractures or adverse events. This thorough follow-up will help determine the effectiveness and safety of these treatments after denosumab discontinuation.

CONDITIONS

Brief Title

The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation

Research Team

F

Fon-Yih Tsuang Clinical Associate Professor, Ph.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here